RxDoctor Payments Data

Laura Hollensworth, MD

Family Medicine · Fairhope, ALNPI 1578584900

Payments from drug & device makers

$10,655in general payments, 2019–2025

Across 664 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Johnson & Johnson$629
  • Lilly USA, LLC$612
  • Pfizer$571
  • Amgen$554
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$10,646100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)115$1,833
Novo Nordisk119$1,516
Johnson & Johnson47$629
Lilly USA, LLC43$612
Pfizer35$571
Amgen28$554
Bayer22$456
AstraZeneca24$370
Otsuka America Pharmaceutical, Inc.19$348
Axsome Therapeutics, Inc.18$346
Boehringer Ingelheim19$327
GSK18$270
Novartis17$247
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$232
Takeda Pharmaceuticals U.S.A., Inc.13$217
Merck12$209
Tris Pharma Inc8$137
Corcept Therapeutics7$122
Amarin Pharma, Inc.5$105
Exact Sciences5$96
Teva Pharmaceuticals USA, Inc.5$91
Lundbeck LLC3$81
Shire North American Group Inc6$79
Supernus Pharmaceuticals, Inc.5$78
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$72
Biohaven Pharmaceutical Holding Company Ltd.3$62
Astellas Pharma US Inc3$61
Boston Scientific2$58
Antares Pharma, Inc.3$57
Neos Therapeutics, LP3$53
Mylan Specialty L.p.3$50
Inspire Medical Systems, Inc.1$50
Phathom Pharmaceuticals, Inc.4$48
Currax Pharmaceuticals LLC3$44
Abbott2$40
Halozyme Inc2$38
Ironshore Pharmaceuticals Inc.2$37
Idorsia Pharmaceuticals US Inc2$36
Sumitomo Pharma America, Inc.2$36
Corium, LLC2$35
IBSA Pharma Inc.2$33
Seqirus USA Inc1$33
Rhythm Pharmaceuticals, Inc.1$26
Sanofi1$23
Sanofi Pasteur Inc.1$20
Optinose US, Inc.1$19
Paratek Pharmaceuticals, Inc.1$18
Tolmar, Inc.1$18
Medtronic1$18
Acadia Pharmaceuticals Inc1$18
Jazz Pharmaceuticals Inc.1$16
Esperion Therapeutics, Inc.1$16
Genentech USA, Inc.1$15
Endo Pharmaceuticals Inc.1$15
Clarus Therapeutics Inc.1$14
Daiichi Sankyo Inc.1$13
Impel Pharmaceuticals Inc.1$13
Upsher-smith Laboratories LLC1$13
Hikma Pharmaceuticals USA1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,655 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$56,604
Medicare patients
93
Services billed
1,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide81$102,221
OzempicSemaglutide73$78,563
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$57,160
EliquisApixaban51$55,057
FarxigaDapagliflozin Propanediol24$24,204
JardianceEmpagliflozin14$17,474
LinzessLinaclotide17$17,070
MyrbetriqMirabegron26$15,384
Aimovig AutoinjectorErenumab-Aooe11$10,205
XareltoRivaroxaban12$10,110
BelsomraSuvorexant18$8,927
Xigduo XrDapaglifloz Propaned/Metformin11$8,820
JanumetSitagliptin Phos/Metformin Hcl11$6,059
TrintellixVortioxetine Hydrobromide11$5,252
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$4,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$612$102,22181 claims
Novo NordiskOzempic$1,516$78,56373 claims
GSKTrelegy Ellipta$270$57,16070 claims
PfizerEliquis$571$55,05751 claims
AstraZenecaFarxiga$370$24,20424 claims
Boehringer IngelheimJardiance$327$17,47414 claims
AbbVieLinzess$1,833$17,07017 claims
Astellas Pharma US IncMyrbetriq$61$15,38426 claims
MerckBelsomra, Janumet$209$14,98729 claims
Johnson & JohnsonXarelto$629$10,11012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$217$5,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →